Clinical effects of long-term metreleptin treatment in patients with lipodystrophy

Endocrine Practice

Volumn 17, Issue 6, 2011, Pages 922-932

  Chan, Jean ^a   Lutz, Karen ^a   Cochran, Elaine ^b   Huang, Wenying ^a   Peters, Yvette ^a   Weyer, Christian ^a   Gorden, Phillip ^b  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METRELEPTIN; TRIACYLGLYCEROL;

ACUTE PANCREATITIS; ADOLESCENT; ADULT; AGED; ALOPECIA; ARTICLE; AUTOIMMUNE HEPATITIS; CHILD; CHOLESTEROL BLOOD LEVEL; CHRONIC HEPATITIS; CHRONIC KIDNEY FAILURE; CONGENITAL GENERALIZED LIPODYSTROPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; FAMILIAL PARTIAL LIPODYSTROPHY; FATIGUE; FATTY LIVER; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLYCEMIC CONTROL; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE URTICARIA; INSULIN RESISTANCE; LIVER DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NONALCOHOLIC FATTY LIVER; PROTEIN BLOOD LEVEL; PROTEINURIA; SCHOOL CHILD; SIDE EFFECT; T CELL LYMPHOMA; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 84862951024     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11229.OR     Document Type: Article

References (19)

1. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:1220-1234. (Pubitemid 38339366)
2. Chan JL, Oral EA. Clinical classifcation and treatment of congenital and acquired lipodystrophy. Endocr Pract. 2010;16:310-323.
3. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystro-phies. J Clin Endocrinol Metab. 2002;87:2395.
4. Reitman ML, Arioglu E, Gavrilova O, Taylor SI. Lipoatrophy revisited. Trends Endocrinol Metab. 2000;11: 410-416.
5. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabe-tes mellitus in mice with congenital lipodystrophy Nature. 1999;401:73-76.
6. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement ther-apy for lipodystrophy N Engl J Med. 2002;346:570-578.
7. Javor ED, Cochran EK, Musso C, Young JR, DePaoli AM, Gorden P. Long-term effcacy of leptin replace-ment in patients with generalized lipodystrophy Diabetes. 2005;54:1994-2002. (Pubitemid 40911261)
8. Musso C, Cochran E, Javor E, Young J, DePaoli AM, Gorden P. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metabolism. 2005; 54:255-263. (Pubitemid 40174856)
9. McDuffe JR, Riggs PA, Calis KA, et al. Effects of exoge-nous leptin on satiety and satiation in patients with lipodys-trophy and leptin insuffciency J Clin Endocrinol Metab. 2004;89:4258-4263. (Pubitemid 39244422)
10. Park JY, Javor ED, Cochran EK, DePaoli AM, Gorden P. Long-term effcacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy Metabolism. 2007;56:508-516. (Pubitemid 46427848)
11. Chong AY, Lupsa BC, Cochran EK, Gorden P. Effcacy of leptin therapy in the different forms of human lipodys-trophy. Diabetologia. 2010;53:27-35.
12. Oral EA, Ruiz E, Andewelt A, et al. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy J Clin Endocrinol Metab. 2002; 87:3110-3117. (Pubitemid 34816352)
13. Moran SA, Patten N, Young JR, et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy Metabolism. 2004;53:513-519. (Pubitemid 38419197)
14. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy J Clin Invest. 2002;109:1345-1350. (Pubitemid 34546899)
15. Javor ED, Ghany MG, Cochran EK, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy Hepatology. 2005;41:753-760. (Pubitemid 40462937)
16. Asilmaz E, Cohen P, Miyazaki M, et al. Site and mecha-nism of leptin action in a rodent form of congenital lipodys-trophy. J Clin Invest. 2004;113:414-424. (Pubitemid 38544185)
17. Unger RH, Zhou YT, Orci L. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci U S A. 1999;96:2327-2332. (Pubitemid 29117914)
18. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimu-lates fatty-acid oxidation by activating AMP-activated pro-tein kinase. Nature. 2002;415:339-343. (Pubitemid 34087557)
19. Gorden P Lupsa BC, Chong AY, Lungu AO. Is there a human model for the "metabolic syndrome" with a defned aetiology? Diabetologia. 2010;53:1534-1536.